Skip to main content

HPA Global

Australian Brands Gain Local Manufacturing Pathway for Next-Generation Complementary Medicines

November 10, 2026

TSI’s new TGA-licensed Brisbane facility brings novel delivery technologies, personalised nutrition and premium formulation capabilities into regional commercial-scale manufacturing

Australian complementary medicine brands now have local access to a unique combination of next-generation product technologies, personalised nutrition and premium formulation capabilities. TSI Group (operating as TSI Pharmaceuticals Pty Ltd) has opened a new Pinkenba manufacturing facility that connects these capabilities with regional production and commercialisation. It provides new ways to differentiate and move innovative concepts to market with fewer disconnected partners.


TSI’s Brisbane expansion is designed to create a fully connected pathway from formulation and format selection through manufacturing and packaging. It addresses practical challenges for Australian brands, including the need to develop products that go beyond conventional formats and support growing interest in complementary medicines manufactured in the Australian market.


“Our strategy is not simply to add manufacturing capacity to the Australian market; it’s to connect innovation with execution,” said John Amarantidis, TSI’s general manager for Australia and New Zealand. “By expanding our end-to-end capabilities here in Brisbane, we can help brands create made-in-Australia complementary medicines that offer a clearer point of difference and respond to changing consumer expectations.”

Through the new Pinkenba facility, brands get full access to TSI’s premium, science-backed ingredients, synergistic formulation support, novel delivery technologies such as FZZR™ granules, a true precision nutrition platform through Tailored Script®, established dosage forms, packaging and commercialisation expertise—all closer to their customers.


“Australian brands are looking for local manufacturing options, but they do not want to compromise on innovation,” Amarantidis said. “TSI’s Australian facility eliminates the complexity, time and risk of managing product development, regulatory requirements, manufacturing and commercialisation across separate partners or distant supply chains. It ensures strong product concepts can be transformed into locally manufactured commercial realities.”


Now in its 30th year, TSI has evolved from a specialty ingredient company into an end-to-end innovation partner. The Australian milestone is part of TSI’s continued investment in an integrated global manufacturing network spanning Asia-Pacific and North America.


The Pinkenba facility holds a Therapeutic Goods Administration manufacturing licence. It complements the existing Brisbane Tailored Script® operation, which is focused on personalised nutrition, and expands the range of complementary medicine concepts TSI can support in Australia.


The opening comes as Australian companies seek products that pair credible science and targeted health outcomes with more convenient and differentiated consumer experiences. TSI’s approach is designed to support that shift, whether the opportunity involves a precision nutrition program, a novel consumer delivery format or a premium formulation focused on specific health outcomes. Brands can access the scientific, technical and manufacturing capabilities required to execute it within the Australian market.


To learn more about TSI Group’s Australian innovation and manufacturing capabilities, or to discuss a new complementary medicine concept, visit tsigroupltd.com or contact the TSI Australia team.

About TSI Group

TSI Group is a global dietary and nutritional solutions provider that helps companies transform consumer and scientific insights into differentiated supplement products. As an innovation leader with 30+ years of expertise, TSI combines science-backed ingredients, advanced delivery technologies, data-driven insights and scalable manufacturing to deliver end-to-end solutions tailored to each partner’s goals. From concept and root-cause formulations to finished forms and commercialization support, TSI Group solves real‑world development and commercialization challenges so customers can launch products with confidence. To learn more, visit TSIGroupltd.com.